

13 October 2015

MMJ's Duncan facility nears completion, MMJ welcomes Australian regulatory shift on medicinal cannabis

- Duncan Facility ready to commence production and awaiting pre-licence inspection by Health Canada
- Following anticipated successful inspection, production expected to commence in the first quarter of 2016
- Management investigating opportunities within Australia in response to regulatory reform announcement by the Victorian Government
- Management team bolstered with the appointment of Mr. Gaelan Bloomfield as Manager of Marketing and PR, Australia to lead the Company's corporate and marketing activities

MMJ PhytoTech Limited (ASX:MMJ) ("MMJ" or the "Company") is pleased to provide investors with an update on the progress at its Duncan facility in Canada.

United Greeneries (a wholly owned subsidiary of MMJ) has completed the required upgrade to its growing facility located in Vancouver and now awaits final pre-licence inspection by Health Canada in line with MMPR licencing requirements. Health Canada's approval is a pre-requisite for production and supply of medicinal cannabis in the Canadian market.

Assuming a successful inspection, MMJ expects to be in a position to commence production in Canada in the first quarter of 2016 – a critical step towards the Company's "Farm to Pharma" strategy.

Encouraging Australian Regulatory Changes for Access to Medicinal Cannabis

The Management Team and Board of MMJ welcome the announcement by the Victorian Government to embark on a State-based cannabis cultivation trial.

ASX RELEASE

The Victorian Government intends to introduce legislation before the end of 2015 to enable access to locally manufactured medicinal cannabis products for a limited number of patients to treat various serious medical conditions.

The Victorian Government's acceptance of the Victorian Law Reform Commission's review provides the Company with the opportunity to establish its operating presence in Australia and Management are currently investigating opportunities within the Australian market place.

Andreas Gedeon, CEO and Managing Director, MMJ PhytoTech stated:

"Our expertise and experience in the medical cannabis market positions us at the forefront of the embryonic industry in Australia. We're encouraged by the Victorian Government's move towards the legalisation of medical cannabis cultivation and as a viable method of treatment for a number of serious conditions including cancer, multiple sclerosis, HIV/AIDS, epilepsy and chronic pain.

"Through our investigations into the opportunity in the market we hope to one day become one of the leading providers of safe and secure medical cannabis in the state of Victoria, Australia."

Appointment of Mr. Gaelan Bloomfield as Marketing Manager & PR, Australia

The Management and Board are pleased to announce the appointment of Gaelan Bloomfield as Manager of Marketing and PR in Australia. Mr Bloomfield's appointment is the first step in an updated strategy to encourage sustainable growth with a focus on corporate maturity.

Mr Bloomfield has gained significant experience through his career supporting both established and emerging companies working in Investment Banking and Management Consulting. He has provided hands on strategic support to some of Australia's largest organisations and has worked in London, Singapore, Australia and the Philippines.

For personal use only

ASX RELEASE

Andreas Gedeon, CEO & Managing Director, MMJ PhytoTech commented:

"I would also like to welcome Mr Bloomfield to the Company. His corporate and consulting expertise will provide us with the direction and necessary advice in the Australian market and is key to supporting our corporate strategy."

To follow Andreas Gedeon on Twitter: @AndreasGedeon

Ends

For more information please contact

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Gaelan Bloomfield
Manager, Marketing & PR
+61 431 303 567
gbloomfield@mmj.ca

For media enquiries

Media & Capital Partners
Asher Moses, Director
+61 438 008 616

About MMJ PhytoTech Limited

MMJ PhytoTech is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company's "Farm to Pharma" strategy.

Its **United Greeneries** subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory.

ASX RELEASE

Satipharm has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.

Through its **PhytoTech Therapeutics** subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.

For personal use only